Intravenous Infusions (XGHA:IIL) Change In Receivables: GHS0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Change In Receivables?

Intravenous Infusions XGHA:IIL -2.33% Change In Receivables is GHS0.00 Mil as of . 20.

Intravenous Infusions's change in receivables for the quarter that ended in . 20 was GHS0.00 Mil. It means Intravenous Infusions's Accounts Receivable stayed the same from . 20 to . 20 .

Intravenous Infusions's change in receivables for the fiscal year that ended in . 20 was GHS0.00 Mil. It means Intravenous Infusions's Accounts Receivable stayed the same from . 20 to . 20 .

Intravenous Infusions's Accounts Receivable for the quarter that ended in . 20 was GHS0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Intravenous Infusions's liquidation value for the six months ended in . 20 was GHS0.00 Mil.

Intravenous Infusions  (XGHA:IIL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Intravenous Infusions's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=/*91
=

2. In Ben Graham's calculation of liquidation value, Intravenous Infusions's accounts receivable are only considered to be worth 75% of book value:

Intravenous Infusions's liquidation value for the quarter that ended in . 20 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=-+0.75 * +0.5 *
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Change In Receivables Related Terms

Intravenous Infusions Change In Receivables Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Change In Receivables Chart

Intravenous Infusions Annual Data
Trend
Change In Receivables

Intravenous Infusions Semi-Annual Data
Change In Receivables

Intravenous Infusions Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Change In Receivables of GHS0.00 Mil as of . 20. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Intravenous Infusions and its competitors.
Is Intravenous Infusions' Change In Receivables too high?
Intravenous Infusions' current Change In Receivables is GHS0.00 Mil.
How does Intravenous Infusions' Change In Receivables compare to PTLF and PCYN?
Intravenous Infusions' Change In Receivables of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Intravenous Infusions and its competitors. Intravenous Infusions's current Change In Receivables is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Change In Receivables of GHS0.00 Mil. The current Change In Receivables is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Change In Receivables is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.